daclatasvir (Daklinza®)

NICE GUIDANCE HAS BEEN WITHDRAWN BECAUSE BRISTOL-MYERS SQUIBB HAS DISCONTINUED DACLATASVIR (DAKLINZA) (NOVEMBER 2019) AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA364) NICE GUIDANCE ISSUED NOVEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology). Daclatasvir (Daklinza®) in combination with other medicinal products is recommended as an option for restricted use within NHS Wales for the treatment of chronic hepatitis C virus (HCV) infection in adults. Use should be restricted to patients with significant fibrosis (METAVIR score ≥ F3) or compensated cirrhosis. Daclatasvir (Daklinza®) in combination with other medicinal products is not recommended for use within NHS Wales outside of this subpopulation.